ENGENE THERAPEUTICS INC (ENGN:NASDAQ)
$8.54 0.03 (0.3525%)
Analysed ENGENE THERAPEUTICS INC (ENGN:NASDAQ) News Sources
enGene Announces Name Change to enGene Therapeutics Inc.
07-04-2026
yahoo.com
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
15-03-2026
marketbeat.com
enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference
15-03-2026
marketbeat.com
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update
15-03-2026
marketbeat.com
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
09-03-2026
yahoo.com
enGene Maps BLA by End-2026, Targets 2027 Launch for Lead NMIBC Therapy at Oppenheimer Conference
28-02-2026
marketbeat.com
enGene to Participate in Upcoming Investor Conferences
20-02-2026
yahoo.com
Jefferies Sets a $28 PT for enGene Holdings Inc. (ENGN)
16-02-2026
yahoo.com
enGene CEO Talks Detalimogene for Community Urology as LEGEND Study Hits Full Enrollment
12-02-2026
marketbeat.com
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
04-02-2026
yahoo.com
What is the current price of ENGENE THERAPEUTICS INC (ENGN:NASDAQ)?
The current price of ENGENE THERAPEUTICS INC (ENGN:NASDAQ) is $8.54.
ENGENE THERAPEUTICS INC (ENGN:NASDAQ) absolute price change since previous trading day?
The absolute price change of ENGENE THERAPEUTICS INC (ENGN:NASDAQ) since the previous trading day is $0.03.
ENGENE THERAPEUTICS INC (ENGN:NASDAQ) percentage price change since previous trading day?
The percentage price change of ENGENE THERAPEUTICS INC (ENGN:NASDAQ) since the previous trading day is 0.3525%.
What is the most recent average sentiment score for ENGENE THERAPEUTICS INC (ENGN:NASDAQ)?
The most recent average sentiment score for ENGENE THERAPEUTICS INC (ENGN:NASDAQ) is 90 out of 100.
What is the most recent average sentiment for ENGENE THERAPEUTICS INC (ENGN:NASDAQ)?
The most recent sentiment for ENGENE THERAPEUTICS INC (ENGN:NASDAQ) is .
SEC-8K** Filing Available For ENGENE THERAPEUTICS INC (ENGN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.